GLYC Glycomimetics Inc

GlycoMimetics Inc is a clinical stage biotechnology company. It is engaged in discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.

As of 05/10/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/10/2014
Outstanding shares:  51,539,010
Average volume:  549,703
Market cap:   $117,508,943
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    38000Q102
ISIN:        US38000Q1022
Sedol:      BG3G1D6
Valuation   (See tab for details)
PE ratio:   -2.56
PB ratio:   0.89
PS ratio:   52.97
Return on equity:   -46.07%
Net income %:   -2,598.22%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy